311 related articles for article (PubMed ID: 15205346)
1. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
[TBL] [Abstract][Full Text] [Related]
2. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.
Kulp SK; Yang YT; Hung CC; Chen KF; Lai JP; Tseng PH; Fowble JW; Ward PJ; Chen CS
Cancer Res; 2004 Feb; 64(4):1444-51. PubMed ID: 14973075
[TBL] [Abstract][Full Text] [Related]
3. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
[TBL] [Abstract][Full Text] [Related]
4. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
Zhu J; Song X; Lin HP; Young DC; Yan S; Marquez VE; Chen CS
J Natl Cancer Inst; 2002 Dec; 94(23):1745-57. PubMed ID: 12464646
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
Ding H; Han C; Zhu J; Chen CS; D'Ambrosio SM
Int J Cancer; 2005 Feb; 113(5):803-10. PubMed ID: 15499625
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
Yang HM; Kim HS; Park KW; You HJ; Jeon SI; Youn SW; Kim SH; Oh BH; Lee MM; Park YB; Walsh K
Circulation; 2004 Jul; 110(3):301-8. PubMed ID: 15238462
[TBL] [Abstract][Full Text] [Related]
7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Levitt RJ; Pollak M
Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.
Lai GH; Zhang Z; Sirica AE
Mol Cancer Ther; 2003 Mar; 2(3):265-71. PubMed ID: 12657721
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
13. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
[TBL] [Abstract][Full Text] [Related]
14. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Li J; Zhu J; Melvin WS; Bekaii-Saab TS; Chen CS; Muscarella P
J Gastrointest Surg; 2006 Feb; 10(2):207-14. PubMed ID: 16455452
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.
Lin HP; Kulp SK; Tseng PH; Yang YT; Yang CC; Chen CS; Chen CS
Mol Cancer Ther; 2004 Dec; 3(12):1671-80. PubMed ID: 15634661
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
Jendrossek V; Handrick R; Belka C
FASEB J; 2003 Aug; 17(11):1547-9. PubMed ID: 12824303
[TBL] [Abstract][Full Text] [Related]
19. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P
Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Shishodia S; Aggarwal BB
Cancer Res; 2004 Jul; 64(14):5004-12. PubMed ID: 15256475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
